CDH2 and cancer: At the molecular level, these substances reduce expression of the epithelial markers E-cadherin, HIF-1α, and/or TGF-β1 and increase expression of the mesenchymal markers vimentin and N-cadherin, which inhibit cancer cell migration and invasion, therefore downregulating the EMT process.